Statistics for Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.

Total visits

views
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. 30

Total visits per month

views
August 2024 0
September 2024 0
October 2024 0
November 2024 0
December 2024 0
January 2025 0
February 2025 0

File Visits

views
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cel.pdf 21